Corporate Presentation

Geron is On Target for a Successful Transition to Commercial Company in 2024 ↑ili↑ PDUFA date of June 16, 2024 for imetelstat in transfusion-dependent (TD) LR-MDS* MAA review completion expected by end-2024, with potential EU approval and launch in 2025 `O- 0-0 geron Imetelstat Ph3 data showed unprecedented durability of transfusion independence (TI) across multiple MDS patient subgroups not addressed by currently available products Additional Ph3 trial of imetelstat ongoing in relapsed/refractory myelofibrosis (R/R MF) with an interim analysis expected first half of 2025 Significant commercial opportunities with TD LR-MDS total addressable market (TAM) >$3.5B and R/R MF TAM >$3.5B in 2031 (U.S./EU)^ *Imetelstat is currently under regulatory review by FDA and EMA for the treatment of transfusion-dependent anemia in adult patients with low- to intermediate-1 risk myelodysplastic syndromes (LR- MDS) who have failed to respond or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAS). Platzbecker, Santini et al. The Lancet 2023 ^see slide 33 for more information on TAM and patient numbers 3

View entire presentation